Sunshine Biopharma Announces $1,361,000 in Debt Reduction

This debt conversion strengthens the financial condition of the Company and conserves the cash on hand for our ongoing research and development activities of our antiviral and anticancer drugs, said, Camille Sebaaly, CFO of Sunshine Biopharma.